You just read:

Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

News provided by

Syndax Pharmaceuticals, Inc.

Nov 06, 2019, 07:00 ET